These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6831828)

  • 21. Renal clearance of sulphinpyrazone in man.
    Lentjes EG; Russel FG; van Ginneken CA
    Eur J Clin Pharmacol; 1986; 31(4):473-8. PubMed ID: 3816927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
    Kuo BS; Ritschel WA
    Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simple and rapid high-performance liquid chromatographic method for the analysis of sulfinpyrazone and four of its metabolites in human plasma.
    Tam YK; Ferguson SM; Yau ML; Wyse DG
    J Chromatogr; 1984 Oct; 310(2):438-44. PubMed ID: 6511862
    [No Abstract]   [Full Text] [Related]  

  • 24. The site of reduction of sulphinpyrazone in the rabbit.
    Strong HA; Renwick AG; George CF
    Xenobiotica; 1984 Oct; 14(10):815-26. PubMed ID: 6506754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The warfarin-sulfinpyrazone interaction: stereochemical considerations.
    Toon S; Low LK; Gibaldi M; Trager WF; O'Reilly RA; Motley CH; Goulart DA
    Clin Pharmacol Ther; 1986 Jan; 39(1):15-24. PubMed ID: 3943265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone.
    Kadar D; Inaba T; Endrenyi L; Johnson GE; Kalow W
    Clin Pharmacol Ther; 1973; 14(4):552-60. PubMed ID: 4723263
    [No Abstract]   [Full Text] [Related]  

  • 27. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
    Ritschel WA; Kuo BS
    Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of the pharmacokinetics of antithrombotic drugs.
    Marks GS
    Thromb Res Suppl; 1983; 4():17-27. PubMed ID: 6356463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of aspirin on the pharmacokinetics of sulfinpyrazone in man.
    Buchanan MR; Endrenyi L; Giles AR; Rosenfeld J
    Thromb Res Suppl; 1983; 4():145-52. PubMed ID: 6579708
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of sulfinpyrazone and its metabolites in human plasma and urine by high-performance liquid chromatography.
    de Vries JX; Staiger C; Wang NS; Schlicht F
    J Chromatogr; 1983 Oct; 277():408-13. PubMed ID: 6643630
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
    Sabia H; Sunkara G; Ligueros-Saylan M; Wang Y; Smith H; McLeod J; Prasad P
    Eur J Clin Pharmacol; 2004 Aug; 60(6):407-12. PubMed ID: 15197517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous determination of sulfinpyrazone and four of its metabolites by high-performance liquid chromatography.
    Jakobsen P; Pedersen AK
    J Chromatogr; 1981 May; 223(2):460-5. PubMed ID: 7251803
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.
    Strong HA; Angus R; Oates J; Sembi J; Howarth P; Renwick AG; George CF
    Clin Pharmacokinet; 1986; 11(5):402-10. PubMed ID: 3780113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.
    O'Reilly RA
    Circulation; 1982 Jan; 65(1):202-7. PubMed ID: 7053283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels and effects of sulfinpyrazone in patients requiring chronic hemodialysis.
    Bern MM; Cavaliere BM; Lukas G
    J Clin Pharmacol; 1980; 20(2-3):107-16. PubMed ID: 7381028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.
    Ritschel WA
    Pharm Res; 1986 Jun; 3(3):173-7. PubMed ID: 24271525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two metabolites of sulphinpyrazone and their identification and determination by mass spectrometry.
    Jakobsen P; Pedersen AK
    J Pharm Pharmacol; 1981 Feb; 33(2):89-92. PubMed ID: 6111605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
    Margulies EH; White AM; Sherry S
    Drugs; 1980 Sep; 20(3):179-97. PubMed ID: 7000488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and disposition of sulfinalol in laboratory animals.
    Benziger DP; Fritz A; Edelson J
    Drug Metab Dispos; 1981; 9(6):493-8. PubMed ID: 6120804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.